Technology

Biosceptre's technology is based on the discovery of what potentially could be the world's first truly universal cancer marker/target – a non-functional cellular receptor (nf-P2X7) that is found on cancer cells but is never present on healthy cells. This breakthrough has prompted the development of a patented range of monoclonal, polyclonal and domain antibodies that target diseased cells whilst having no adverse effect on surrounding healthy cells. The technology is unique in its ability to target all forms of tumors tested to date (both solid and blood based tumors) and has the potential to radically change the way cancer is diagnosed and treated in humans and other mammals.

Novel Marker nf-P2X7

P2X7 is a major cellular receptor responsible for normal programmed cell death (apoptosis). At the time an aging cell is ready to die, P2X7 is expressed on the cell wall triggering a sequence of biological processes that leads to apoptosis.  This process is so fast that, under normal circumstances, P2X7 cannot be detected on the cell wall.
Cancer cells have abnormal “death receptors” (nf-P2X7) on their surface and programmed cell death (apoptosis) does not occur. Biosceptre’s custom-made antibodies attach themselves to these abnormal receptors and this combination then appears to result in death of the cancer cells – perhaps by re-initiation of normal apoptosis, perhaps by another mechanism such as attracting lymphocytes and macrophages which are involved in killing cells. This is depicted in the figure below:

Universal Cancer Marker